Protox collaborates with BrainLAB for Brain Cancer Program



    VANCOUVER, Nov. 14 /CNW/ - Protox Therapeutics Inc. (TSX-V: PRX) today
announced that it has entered into a collaborative research and clinical
development agreement with BrainLAB AG for use of the BrainLAB proprietary
drug delivery software iPlan(R) Flow in the planned pre-pivotal primary brain
cancer clinical trial of PRX321. Terms of the final agreement have not been
released.
    As part of the agreement, BrainLAB will supply and install its iPlan Flow
software at all clinical sites participating in the pre-pivotal trial. The
software will incorporate patient-specific information to monitor and
potentially predict drug distribution in and around the brain tumor. Using the
iPlan Flow software, neurosurgeons will be able to better plan treatments and
optimize catheter placement for ideal delivery and distribution of PRX321.
    "We are very pleased to have secured this agreement with BrainLAB and see
this as an important step in the commercial development of PRX321 for the
treatment of primary and metastatic brain cancer." said Dr. Fahar Merchant,
President and Chief Executive Officer of Protox. "The use of this software
should allow for patient-specific treatment resulting in optimal delivery and
distribution of PRX321 which in turn could lead to more favorable outcomes in
patients with this disease."
    "With Protox, we have found one of the most experienced teams for
targeted drug delivery as a key partner in the development of therapies for
brain tumors," said Dr. Christoph Pedain, Director of BrainLAB Pharmaceutical
Solutions. "This cooperation provides the possibility to improve delivery of
PRX321 to the brain by incorporating promising new BrainLAB technologies.
These technologies are designed to ease adoption and improve standardization
among participating clinical centers."
    In addition to the iPlan Flow software, BrainLAB will also provide
hospital support services during this clinical study by installing computer
hardware and software at the study sites, provide support and training for the
participating neurosurgeons and perform data collection and analysis of study
results.

    Facts about brain cancer

    The American Cancer Society estimates that in 2007 approximately 20,000
people will be diagnosed with brain cancer and 12,500 will die as a result of
the disease in the United States. Primary brain cancer is currently treated
with an aggressive combination approach that includes surgery, radiation
therapy and chemotherapy. Although treatment may prolong survival, most
malignant brain tumors are not curable. As such, a significant unmet need
exists for this form of cancer.

    About BrainLAB

    BrainLAB develops, manufactures and markets software-driven medical
technology that enables procedures that are more precise, less invasive, and
also less expensive than traditional treatments. Among the core products are
image-guided systems that provide highly accurate real-time information used
for navigation during surgical procedures. This utility has been further
expanded to serve as a computer terminal for physicians to more effectively
access and interpret diagnostic scans and other digital medical information
for better informed decisions. BrainLAB solutions allow expansion from a
single system to operating suites to digitally integrated hospitals covering
all subspecialties from neurosurgery, orthopedics, ENT, CMF to spine & trauma
and oncology. With more than 2,950 systems installed in over 70 countries,
BrainLAB is a market leader in image-guided technology. The privately held
BrainLAB group, founded in 1989, is headquartered in Munich, Germany and today
employs more than 950 people in 16 offices across Europe, Asia, Australia,
North and South America.
    For more information, visit BrainLAB at www.brainlab.com

    About PRX321

    PRX321 is a novel targeted protein in which a cytokine, interleukin-4
(IL-4), is linked to a Pseudomonas exotoxin, a potent substance that can
destroy cancer cells. The IL-4 portion of the compound binds to IL-4 receptors
found on the surface of various types of cancer cells. The drug subsequently
enters the target cell where the toxin component causes cell death by
inhibiting protein synthesis. PRX321 is in clinical development for the
treatment of primary brain cancer, specifically malignant astrocytoma and
glioblastoma multiforme (GBM). Results from a Phase 2a clinical trial
completed in patients with recurrent and progressive GBM showed potent
anti-tumor effects without drug-related systemic toxicity in the majority of
patients. Based on encouraging safety and efficacy results from this trial,
Protox is preparing to conduct a pre-pivotal clinical trial.

    About Protox

    Protox Therapeutics is a leader in advancing novel, targeted protein
toxin therapeutics for the treatment of cancer and other proliferative
diseases. Two novel drug candidates derived from the company's INxin(TM) and
PORxin(TM) platforms are being developed in three clinical programs. A Phase
2a clinical trial evaluating PRX321 (INxin) for the treatment of primary brain
cancer has been completed and the drug has received Fast Track Designation and
Orphan Drug Status from the US FDA. Phase 1 clinical trials evaluating PRX302
(PORxin) have been completed for the treatment of localized prostate cancer
and benign prostatic hyperplasia (enlarged prostate).

    NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS
    RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE
    ADEQUACY OR ACCURACY OF THIS RELEASE.

    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.





For further information:

For further information: James Beesley, Director, Investor Relations,
Protox Therapeutics, (604) 688-0199, jbeesley@protoxtherapeutics.com; Michael
Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241,
mmoore@equicomgroup.com; Dr. Christoph Pedain, Director Pharmaceutical
Solutions, BrainLAB AG, + 49 89 99 15 68 154, christoph.pedain@brainlab.com

Organization Profile

Sophiris Bio, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890